Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Petter Olsson

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
NPJ Primary Care Respiratory Medicine|February 5, 2016
TOTALL: high cost of allergic rhinitis-a national Swedish population-based questionnaire studyLars-Olaf Cardell, Petter Olsson, Morgan Andersson, et al.
Journal of Geriatric Psychiatry and Neurology|January 27, 2016
Cognitive Function in Older Suicide Attempters and a Population-Based Comparison GroupPetter Olsson, Stefan Wiktorsson, Simona Sacuiu, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|June 8, 2021
HealthSWEDE: costs with sublingual immunotherapy-a Swedish questionnaire studyPetter Olsson, Carl Skröder, Lars Ahlbeck, et al.
Respiratory Research|September 12, 2018
 Identifying the associated risks of pneumonia in COPD patients: ARCTIC an observational studyChrister Janson, Gunnar Johansson, Björn Ställberg, et al.
Respiratory Research|April 24, 2020
Impact of baseline symptoms and health status on COPD exacerbations in the FLAME studyAlexander J Mackay, Konstantinos Kostikas, Nicolas Roche, et al.
Respiratory Research|December 13, 2017
Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish populationLeif Bjermer, Job F M van Boven, Madlaina Costa-Scharplatz, et al.
International Journal of Chronic Obstructive Pulmonary Disease|June 14, 2019
Impact of COPD diagnosis timing on clinical and economic outcomes: the ARCTIC observational cohort studyKjell Larsson, Christer Janson, Björn Ställberg, et al.
Acta Oto-Laryngologica|April 8, 2016
Treatment of idiopathic rhinitis with kinetic oscillations - a multi-centre randomized controlled studyAnders Ehnhage, Pernilla Sahlstrand Johnsson, Cecilia Ahlström-Emanuelsson, et al.
American Journal of Respiratory and Critical Care Medicine|March 10, 2017
Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME TrialNicolas Roche, Kenneth R Chapman, Claus F Vogelmeier, et al.
Respirology (Carlton, Vic.)|August 4, 2018
Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trialPeter A Frith, Samiha Ashmawi, Srikanth Krishnamurthy, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
NPJ Primary Care Respiratory Medicine|February 5, 2016
TOTALL: high cost of allergic rhinitis-a national Swedish population-based questionnaire studyLars-Olaf Cardell, Petter Olsson, Morgan Andersson, et al.
Journal of Geriatric Psychiatry and Neurology|January 27, 2016
Cognitive Function in Older Suicide Attempters and a Population-Based Comparison GroupPetter Olsson, Stefan Wiktorsson, Simona Sacuiu, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|June 8, 2021
HealthSWEDE: costs with sublingual immunotherapy-a Swedish questionnaire studyPetter Olsson, Carl Skröder, Lars Ahlbeck, et al.
Respiratory Research|September 12, 2018
 Identifying the associated risks of pneumonia in COPD patients: ARCTIC an observational studyChrister Janson, Gunnar Johansson, Björn Ställberg, et al.
Respiratory Research|April 24, 2020
Impact of baseline symptoms and health status on COPD exacerbations in the FLAME studyAlexander J Mackay, Konstantinos Kostikas, Nicolas Roche, et al.
Respiratory Research|December 13, 2017
Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish populationLeif Bjermer, Job F M van Boven, Madlaina Costa-Scharplatz, et al.
International Journal of Chronic Obstructive Pulmonary Disease|June 14, 2019
Impact of COPD diagnosis timing on clinical and economic outcomes: the ARCTIC observational cohort studyKjell Larsson, Christer Janson, Björn Ställberg, et al.
Acta Oto-Laryngologica|April 8, 2016
Treatment of idiopathic rhinitis with kinetic oscillations - a multi-centre randomized controlled studyAnders Ehnhage, Pernilla Sahlstrand Johnsson, Cecilia Ahlström-Emanuelsson, et al.
American Journal of Respiratory and Critical Care Medicine|March 10, 2017
Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME TrialNicolas Roche, Kenneth R Chapman, Claus F Vogelmeier, et al.
Respirology (Carlton, Vic.)|August 4, 2018
Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trialPeter A Frith, Samiha Ashmawi, Srikanth Krishnamurthy, et al.
Pageof 4